CD274 and non-small cell lung carcinoma: For example, the CodeBreak100 clinical trial that included 126 patients with metastatic non-small cell lung cancer, of whom 81% had received other targeted therapy with PD-1 or PD-L1 inhibitors, a response was observed in up to 37.1% of patients with a median response of 11.1 months and a median survival of 12.5 months with sotorasib [111].